Cartesian Therapeutics (Cartesian Therapeutics) Accounts Receivable : $2.01 Mil (As of Mar. 2024)

View and export this data going back to 2016. Start your Free Trial

What is Cartesian Therapeutics Accounts Receivable?

Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Cartesian Therapeutics's accounts receivables for the quarter that ended in Mar. 2024 was $2.01 Mil.

Accounts receivable can be measured by Days Sales Outstanding. Cartesian Therapeutics's Days Sales Outstanding for the quarter that ended in Mar. 2024 was 31.34.

In Ben Graham's calculation of Net-Net Working Capital, accounts receivable are only considered to be worth 75% of book value. Cartesian Therapeutics's Net-Net Working Capital per share for the quarter that ended in Mar. 2024 was $-61.11.

Cartesian Therapeutics Accounts Receivable Historical Data

The historical data trend for Cartesian Therapeutics's Accounts Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cartesian Therapeutics Accounts Receivable Chart

Cartesian Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Accounts Receivable

Get a 7-Day Free Trial

5.00

7.22

9.91

6.60

5.87

Cartesian Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Accounts Receivable	Get a 7-Day Free Trial															6.84	5.39	4.90	5.87	2.01

Cartesian Therapeutics Accounts Receivable Calculation

Accounts Receivable is money owed to a business by customers and shown on its Balance Sheet as an asset.

Cartesian Therapeutics Accounts Receivable Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's accounts receivables are being managed.

Cartesian Therapeutics's Days Sales Outstanding for the quarter that ended in Mar. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	2.006	/	5.84	*	91
=	31.34

2. In Ben Graham's calculation of Net-Net Working Capital (NNWC), Cartesian Therapeutics's accounts receivable are only considered to be worth 75% of book value:

Cartesian Therapeutics's Net-Net Working Capital Per Share for the quarter that ended in Mar. 2024 is calculated as:

	Net-Net Working Capital Per Share
=	(Cash And Cash Equivalents	+	0.75 * Accounts Receivable	+	0.5 * Total Inventories	-	Total Liabilities
-	Preferred Stock	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(103.418	+	0.75 * 2.006	+	0.5 * 0	-	442.007
-	0	-	0)	/	5.51584
=	-61.11

Be Aware

Net receivables tells us a great deal about the different competitors in the same industry. In competitive industries, some attempt to gain advantage by offering better credit terms, causing increase in sales and receivables.

If company consistently shows lower % Net receivables to gross sales than competitors, then it usually has some kind of competitive advantage which requires further digging.

Average Days Sales Outstanding is a good indicator for measuring a company's sales channel and customers. A company may book great revenue and earnings growth but never receive payment from their customers. This may force a write-off in the future and depress future earnings.

Cartesian Therapeutics Accounts Receivable Related Terms

Thank you for viewing the detailed overview of Cartesian Therapeutics's Accounts Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.

Cartesian Therapeutics (Cartesian Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cartesian Therapeutics Inc (NAS:RNAC) » Definitions » Accounts Receivable

Comparable Companies

Traded in Other Exchanges

1S7:Germany

Address

65 Grove Street, Watertown, MA, USA, 02472

Website

https://www.selectabio.com

Cartesian Therapeutics Inc is a clinical-stage biopharmaceutical company. The company uses its ImmTOR immune tolerance platform, which is designed to give rise to antigen-specific immunity, mitigating unwanted immune responses. Its product pipeline includes MMA-101, SEL-212 for Chronic Severe Gout, SEL-313 for Ornithine Transcarbamylase Deficiency (OTC), and others.

Executives

Carsten Brunn	director, officer: President & CEO	C/O SELECTA BIOSCIENCES, INC., 480 ARSENAL WAY, WATERTOWN MA 02472
Peter G Traber	officer: Chief Medical Officer	430 THAMER LANE, HOUSTON TX 77025
Takashi Kei Kishimoto	officer: Chief Scientific Officer	480 ARSENAL ST., BUILDING ONE, WATERTOWN MA 02472
Lloyd P. Johnston	officer: COO and SVP, R&D	480 ARSENAL ST., BUILDING ONE, WATERTOWN MA 02472
Blaine Davis	officer: Chief Financial Officer	C/O ARTARA THERAPEUTICS, INC., 1 LITTLE WEST 12TH STREET, NEW YORK NY 10014
Carrie Smith Cox	director	SCHERING-PLOUGH CORPORATION, 2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Timothy C Barabe	director	C/O ARQULE, INC., 1 WALL STREET, 6TH FLOOR, BURLINGTON MA 01803
Timothy A Springer	director	36 WOODMAN ROAD, CHESTNUT HILL MA 02467
Kevin Tan	officer: Chief Financial Officer	20 HICKORY ROAD, WELLESLEY MA 02482
Nishan M Desilva	director	11119 NORTH TORREY PINES RD STE 200, LA JOLLA CA 92037
Ann K. Donohue	officer: VP Finance	C/O SELECTA BIOSCIENCES, INC., 480 ARSENAL WAY, BUILDING ONE, WATERTOWN MA 02472
Bradford D. Dahms	officer: Chief Financial Officer	C/O SELECTA BIOSCIENCES, INC., 480 ARSENAL WAY, WATERTOWN MA 02472
Goran Ando	director
Scott Dunseth Myers	director	C/O CASCADIAN THERAPEUTICS, INC., 3101 WESTERN AVE., SUITE 600, SEATTLE WA 98121
Elona Esq. Kogan	officer: General Counsel	C/O SEER, INC., 3800 BRIDGE PARKWAY, SUITE 102, REDWOOD CITY CA 94065